Menu

Intercept stock surges on positive data from liver fibrosis drug study

By Staff Correspondent |

Intercept Pharmaceuticals (ICPT) had surged about 25% in the pre-market session on Tuesday after the biopharma company announced positive topline results from the phase 3 study for the treatment of patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). Based on these results, Intercept intends to file for approval in the U.S. and Europe in the latter half of 2019.

Shares of Intercept traded down $0.38 on Friday and ended at $110.82. The stock, which hit a yearly high ($133.74) in early October, had surged about 25% in the pre-market trading today. The stock, which was expected to surpass its previous 52-week high today, didn’t carry the pre-market momentum and opened up 19% at $131.67.

“We are thrilled to report the first positive registrational Phase 3 study results in patients with NASH, a devastating disease that is on track to become a leading cause of liver transplant in coming years,” said CEO Mark Pruzanski.

Also read: Intercept Pharmaceuticals (ICPT) Q3 2018 earnings call transcript

The company plans to present the study results at the European Association for the Study of the Liver (EASL): The International Liver Congress 2019, which is scheduled to take place 10-14 April 2019 in Vienna, Austria.

It’s worth noting that biotech giant Gilead Sciences (GILD) reported its failure of late-stage study in patients with compensated cirrhosis due to NASH. The NASH market is projected to experience rapid growth in the future and many pharma companies are investing heavily in this area.

According to DelveInsight, the NASH market will experience significant annual growth over the 2016-2028 study period, as major-market sales increase up to $30.1 billion by 2028. The report also states that Intercept’s OCA is expected to grab maximum market share.

Intercept’s peers Viking Therapeutics (VKTX) and CymaBay Therapeutics (CBAY) also jumped today in pre-market hours, buoyed by the positive data from the New York-based pharma company.

 

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

 

 

 

Advertisement

230 responses to “Intercept stock surges on positive data from liver fibrosis drug study”

  1. Fiverr Earn

    […]Wonderful story, reckoned we could combine a couple of unrelated data, nevertheless genuinely worth taking a search, whoa did one understand about Mid East has got extra problerms also […]

  2. technology

    […]Wonderful story, reckoned we could combine a couple of unrelated data, nonetheless definitely worth taking a appear, whoa did one discover about Mid East has got far more problerms as well […]

  3. multisbo slot

    […]Wonderful story, reckoned we could combine a number of unrelated information, nonetheless seriously really worth taking a search, whoa did one particular learn about Mid East has got much more problerms also […]

  4. FUE

    […]we like to honor several other world wide web sites on the net, even if they aren’t linked to us, by linking to them. Beneath are some webpages worth checking out[…]

  5. FiverrEarn

    […]Wonderful story, reckoned we could combine a number of unrelated information, nevertheless seriously worth taking a search, whoa did one particular study about Mid East has got more problerms too […]

  6. Fresh

    […]Wonderful story, reckoned we could combine a couple of unrelated data, nonetheless genuinely worth taking a search, whoa did a single master about Mid East has got extra problerms as well […]

  7. sonovive scam

    […]Wonderful story, reckoned we could combine a number of unrelated information, nevertheless seriously really worth taking a look, whoa did a single discover about Mid East has got more problerms also […]

  8. mzplay

    […]we prefer to honor many other net web pages around the internet, even when they aren’t linked to us, by linking to them. Underneath are some webpages really worth checking out[…]

  9. playnet app

    […]Wonderful story, reckoned we could combine a couple of unrelated information, nonetheless truly really worth taking a appear, whoa did a single study about Mid East has got more problerms as well […]

  10. 늑대닷컴

    […]Wonderful story, reckoned we could combine a couple of unrelated data, nonetheless really really worth taking a look, whoa did one discover about Mid East has got extra problerms at the same time […]

Leave a Reply

Top